Oxybutynin controlled release vaginal - Teva Pharmaceutical Industries

Drug Profile

Oxybutynin controlled release vaginal - Teva Pharmaceutical Industries

Alternative Names: DR-3001; Enhance UI; Oxybutynin transvaginal ring (TVR) - Teva

Latest Information Update: 09 Feb 2015

Price : $50

At a glance

  • Originator Duramed Pharmaceuticals Inc
  • Developer Teva Pharmaceutical Industries
  • Class Antispasmodics; Carbocyclic acids; Mandelic acids; Small molecules
  • Mechanism of Action Cholinergic receptor antagonists; Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Overactive bladder

Most Recent Events

  • 31 Dec 2013 Discontinued - Phase-III for Overactive bladder in USA and Canada (Vaginal)
  • 07 May 2012 Efficacy data from a phase II trial in Overactive bladder presented at the American Congress of Obstetricians and Gynecologists Annual Clinical Meeting (ACOG-2012)
  • 31 Jul 2010 Duramed completes a phase III safety extension trial (NCT00782769) in Overactive bladder in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top